Ontology type: schema:ScholarlyArticle Open Access: True
2020-10-15
AUTHORSShuichi Ito, Tomoko Torii, Akihiro Nakajima, Takeshi Iijima, Hiroshi Murano, Hideki Horiuchi, Hisashi Yamanaka, Masataka Honda
ABSTRACTBackgroundAlthough gout is rare in children, chronic sustained hyperuricemia can lead to monosodium urate deposits progressing to gout, just as in adults. This study assessed prevalence and characteristics of gout and asymptomatic hyperuricemia, and incidence of gouty arthritis in the pediatric population, using data from Japanese health insurance claims. The diagnosis and treatment of pediatric gout and hyperuricemia were analyzed, and specific characteristics of those patients were assessed. Since Japanese guidelines recommend treatment with uric acid lowering drugs for asymptomatic hyperuricemia as well as for gout, these data were also used to investigate the real-world use of uric acid lowering drugs in a pediatric population.MethodsThis cross-sectional study was based on a 2016–2017 Japanese health insurance claims database, one of the largest epidemiology claims databases available in Japan, which included 356,790 males and 339,487 females 0–18 years of age. Outcomes were measured for prevalence, patient characteristics, treatment with uric acid lowering drugs for gout and asymptomatic hyperuricemia, and prevalence and incidence of gouty arthritis. Because uric acid can be elevated by some forms of chemotherapy, data from patients under treatment for malignancies were excluded from consideration.ResultsTotal prevalence of gout and asymptomatic hyperuricemia in 0–18 year-olds was 0.040% (276/696,277 patients), with gout prevalence at 0.007% (48/696,277) and asymptomatic hyperuricemia at 0.033% (228/696,277). Prevalence of gout and asymptomatic hyperuricemia was highest in adolescent males, at 0.135% (176/130,823). The most common comorbidities for gout and asymptomatic hyperuricemia were metabolic syndrome at 42.8% (118/276) and kidney disease at 34.8% (96/276). Of the patients diagnosed with gout or asymptomatic hyperuricemia, 35.1% (97/276) were treated with uric acid lowering drugs. Gouty arthritis developed in 43.8% (21/48) of gout patients during the study, at an incidence of 0.65 flares/person-year.ConclusionsEven the pediatric population could be affected by asymptomatic hyperuricemia, gout, and gouty arthritis, and uric acid lowering drugs are being used in this population even though those drugs have not been approved for pediatric indications. Such off-label use may indicate a potential need for therapeutic agents in this population.Trial registrationUMIN000036029. More... »
PAGES481
http://scigraph.springernature.com/pub.10.1186/s12887-020-02379-0
DOIhttp://dx.doi.org/10.1186/s12887-020-02379-0
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1131721512
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/33059648
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Clinical Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Public Health and Health Services",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adolescent",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Child",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Child, Preschool",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Cross-Sectional Studies",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gout",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hyperuricemia",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Infant",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Insurance, Health",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Japan",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Prevalence",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Uric Acid",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Fukuura 3-9, Kanazawa-ku, 236-0004, Yokohama-shi, Kanagawa, Japan",
"id": "http://www.grid.ac/institutes/grid.268441.d",
"name": [
"Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Fukuura 3-9, Kanazawa-ku, 236-0004, Yokohama-shi, Kanagawa, Japan"
],
"type": "Organization"
},
"familyName": "Ito",
"givenName": "Shuichi",
"id": "sg:person.012302533312.63",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012302533312.63"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical Science Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Medical Science Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Torii",
"givenName": "Tomoko",
"id": "sg:person.015243315571.90",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015243315571.90"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pharmaceutical Development Administration Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Pharmaceutical Development Administration Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Nakajima",
"givenName": "Akihiro",
"id": "sg:person.015427442431.82",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015427442431.82"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pharmaceutical Development Coordination Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Pharmaceutical Development Coordination Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Iijima",
"givenName": "Takeshi",
"id": "sg:person.010133205371.47",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010133205371.47"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pharmaceutical Development Coordination Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Pharmaceutical Development Coordination Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Murano",
"givenName": "Hiroshi",
"id": "sg:person.011526146371.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011526146371.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Medical Science Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.419889.5",
"name": [
"Medical Science Department, Teijin Pharma Limited, Kasumigaseki Common Gate West Tower, Kasumigaseki 3-2-1, Chiyoda-ku, 100-8585, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Horiuchi",
"givenName": "Hideki",
"id": "sg:person.012440353373.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012440353373.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Rheumatology, Sanno Medical Center, Akasaka 8-5-35, Minato-ku, 107-0052, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.511745.3",
"name": [
"Rheumatology, Sanno Medical Center, Akasaka 8-5-35, Minato-ku, 107-0052, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Yamanaka",
"givenName": "Hisashi",
"id": "sg:person.01332171373.37",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332171373.37"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Clinical Research Support Center, Tokyo Metropolitan Children\u2019s Medical Center, Musashidai 2-8-29, Fuchu-shi, 183-8561, Tokyo, Japan",
"id": "http://www.grid.ac/institutes/grid.417084.e",
"name": [
"Clinical Research Support Center, Tokyo Metropolitan Children\u2019s Medical Center, Musashidai 2-8-29, Fuchu-shi, 183-8561, Tokyo, Japan"
],
"type": "Organization"
},
"familyName": "Honda",
"givenName": "Masataka",
"id": "sg:person.01300112777.86",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01300112777.86"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1186/1546-0096-12-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1046690430",
"https://doi.org/10.1186/1546-0096-12-1"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf01957519",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006687747",
"https://doi.org/10.1007/bf01957519"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/bf00858973",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1039108738",
"https://doi.org/10.1007/bf00858973"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00256-013-1771-8",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1037199960",
"https://doi.org/10.1007/s00256-013-1771-8"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00467-010-1599-6",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1003290619",
"https://doi.org/10.1007/s00467-010-1599-6"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00296-011-2106-5",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040511723",
"https://doi.org/10.1007/s00296-011-2106-5"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1038/ejhg.2012.304",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1040366640",
"https://doi.org/10.1038/ejhg.2012.304"
],
"type": "CreativeWork"
}
],
"datePublished": "2020-10-15",
"datePublishedReg": "2020-10-15",
"description": "BackgroundAlthough gout is rare in children, chronic sustained hyperuricemia can lead to monosodium urate deposits progressing to gout, just as in adults. This study assessed prevalence and characteristics of gout and asymptomatic hyperuricemia, and incidence of gouty arthritis in the pediatric population, using data from Japanese health insurance claims. The diagnosis and treatment of pediatric gout and hyperuricemia were analyzed, and specific characteristics of those patients were assessed. Since Japanese guidelines recommend treatment with uric acid lowering drugs for asymptomatic hyperuricemia as well as for gout, these data were also used to investigate the real-world use of uric acid lowering drugs in a pediatric population.MethodsThis cross-sectional study was based on a 2016\u20132017 Japanese health insurance claims database, one of the largest epidemiology claims databases available in Japan, which included 356,790 males and 339,487 females 0\u201318\u2009years of age. Outcomes were measured for prevalence, patient characteristics, treatment with uric acid lowering drugs for gout and asymptomatic hyperuricemia, and prevalence and incidence of gouty arthritis. Because uric acid can be elevated by some forms of chemotherapy, data from patients under treatment for malignancies were excluded from consideration.ResultsTotal prevalence of gout and asymptomatic hyperuricemia in 0\u201318\u2009year-olds was 0.040% (276/696,277 patients), with gout prevalence at 0.007% (48/696,277) and asymptomatic hyperuricemia at 0.033% (228/696,277). Prevalence of gout and asymptomatic hyperuricemia was highest in adolescent males, at 0.135% (176/130,823). The most common comorbidities for gout and asymptomatic hyperuricemia were metabolic syndrome at 42.8% (118/276) and kidney disease at 34.8% (96/276). Of the patients diagnosed with gout or asymptomatic hyperuricemia, 35.1% (97/276) were treated with uric acid lowering drugs. Gouty arthritis developed in 43.8% (21/48) of gout patients during the study, at an incidence of 0.65 flares/person-year.ConclusionsEven the pediatric population could be affected by asymptomatic hyperuricemia, gout, and gouty arthritis, and uric acid lowering drugs are being used in this population even though those drugs have not been approved for pediatric indications. Such off-label use may indicate a potential need for therapeutic agents in this population.Trial registrationUMIN000036029.",
"genre": "article",
"id": "sg:pub.10.1186/s12887-020-02379-0",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1024635",
"issn": [
"1471-2431"
],
"name": "BMC Pediatrics",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "1",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "20"
}
],
"keywords": [
"asymptomatic hyperuricemia",
"prevalence of gout",
"pediatric population",
"cross-sectional study",
"gouty arthritis",
"uric acid",
"Japanese health insurance database",
"MethodsThis cross-sectional study",
"Health Insurance Database",
"form of chemotherapy",
"monosodium urate deposits",
"Japanese health insurance",
"years of age",
"Japanese health insurance claims",
"health insurance claims",
"patient characteristics",
"common comorbidities",
"metabolic syndrome",
"gout patients",
"insurance database",
"claims database",
"gout prevalence",
"kidney disease",
"label use",
"pediatric indications",
"Japanese guidelines",
"hyperuricemia",
"arthritis",
"urate deposits",
"patients",
"gout",
"prevalence",
"therapeutic agents",
"real-world use",
"drugs",
"incidence",
"health insurance",
"adolescent males",
"females 0",
"treatment",
"potential need",
"insurance claims",
"population",
"males",
"comorbidities",
"chemotherapy",
"chronic",
"malignancy",
"syndrome",
"disease",
"study",
"diagnosis",
"database",
"ConclusionsEven",
"adults",
"age",
"outcomes",
"children",
"acid",
"indications",
"guidelines",
"years",
"agents",
"data",
"use",
"insurance",
"specific characteristics",
"characteristics",
"flares",
"need",
"Japan",
"consideration",
"form",
"claims",
"deposits"
],
"name": "Prevalence of gout and asymptomatic hyperuricemia in the pediatric population: a cross-sectional study of a Japanese health insurance database",
"pagination": "481",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1131721512"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1186/s12887-020-02379-0"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"33059648"
]
}
],
"sameAs": [
"https://doi.org/10.1186/s12887-020-02379-0",
"https://app.dimensions.ai/details/publication/pub.1131721512"
],
"sdDataset": "articles",
"sdDatePublished": "2022-05-10T10:28",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_876.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1186/s12887-020-02379-0"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12887-020-02379-0'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12887-020-02379-0'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12887-020-02379-0'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12887-020-02379-0'
This table displays all metadata directly associated to this object as RDF triples.
286 TRIPLES
22 PREDICATES
123 URIs
107 LITERALS
21 BLANK NODES